2. Salesforce Inc. (NYSE:CRM)
Salesforce Inc. (NYSE: CRM) takes the No. 2 position among cheap stocks to buy for the next 10 years because it remains one of the biggest enterprise software companies in the world and is now pushing hard into artificial intelligence through platforms designed to make customer data more useful, connected, and actionable. Trading at $165.84, Salesforce has spent years building its position in customer relationship management, sales software, service tools, marketing platforms, commerce applications, analytics, and cloud-based business systems. Now, with Agentforce and trusted AI becoming more central to the company’s strategy, Salesforce is trying to prove that it can remain essential in the next generation of enterprise software.
On April 28, Salesforce and Moderna announced a new partnership to unify the biotech company’s global commercial operations through Agentforce Life Sciences. This is a serious development because life sciences companies operate in one of the most complex commercial environments in the world. They deal with healthcare providers, regulatory rules, patient services, medical information, global markets, field teams, regional systems, and sensitive data. Moderna needs a connected digital foundation that can support growth without creating operational confusion. Salesforce is positioning Agentforce Life Sciences as that foundation.
The partnership aims to create a single connected platform that integrates data from sources such as SAP and e-commerce systems to provide a 360-degree view of healthcare provider interactions. That phrase, “360-degree view,” is common in enterprise software, but in healthcare and biotech, it can be especially valuable. If commercial teams can see accurate provider interactions, customer history, product engagement, service needs, and regional activity in one place, they can make better decisions faster. For Moderna, that could mean more coordinated field services, better customer engagement, and a more scalable commercial infrastructure as it expands globally.
Salesforce’s platform will use AI and automation to deliver “next best actions” and automated cycle planning. This means global teams can receive real-time recommendations based on data rather than relying only on manual planning or fragmented regional systems. In a competitive life sciences market, those recommendations can help field teams prioritize outreach, personalize campaigns, and improve service quality. By consolidating regional systems and incorporating IQVIA OneKey reference data, the platform is designed to create a secure and trusted source of truth for commercial activities.
That is an important part of the Salesforce investment thesis. The company is not simply adding AI features for marketing appeal. It is trying to embed AI into real business processes where companies need productivity, compliance, personalization, and operational efficiency. If Agentforce can become a trusted AI layer across industries such as healthcare, financial services, retail, manufacturing, and government, Salesforce could unlock another long-term growth cycle. Investors searching for AI software stocks, cloud stocks, CRM stocks, and undervalued technology stocks should pay attention to whether Agentforce adoption turns into meaningful revenue and customer retention.
The Moderna architecture is also built on an open ecosystem that connects medical, commercial, and patient service operations without vendor lock-in. This is important because large enterprises do not want to be trapped in closed systems that cannot communicate with existing software. Salesforce’s ability to work across platforms could help it stay relevant as companies modernize at different speeds and with different technology stacks. The more flexible Salesforce becomes, the stronger its long-term position may be.
For investors, Salesforce’s long-term appeal comes from the durability of customer relationships and the increasing need for unified data. Most companies already have too much information scattered across too many systems. They need platforms that can organize that data, automate workflows, and help teams act quickly. Salesforce’s Customer 360 platform, powered by data tools and trusted AI, is built exactly for that type of problem.
Over the next 10 years, Salesforce’s biggest challenge will be proving that AI can drive real enterprise value rather than just hype. The Moderna partnership is a useful example because it shows AI being applied to a serious operational problem in a high-value industry. If Salesforce can repeat this across more sectors, CRM could remain one of the best long-term software stocks to buy and hold. The stock may be down in the short term, but for patient investors, Salesforce still offers a rare mix of scale, recurring revenue, enterprise trust, AI optionality, and global market reach.
Click next to see the following stock...
